Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Bimekizumab
Bimzelx
Routinely available
SMC (SMC2410)
25/11/2025
Indication
Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. SMC restriction: for patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these ...
Therapeutic Area
Skin
Status Description
Routinely available in line with national guidance
Formulation
solution for injection in pre-filled syringe and pre-filled pen
Comments
.
Link to Advice
Advice Published
08/11/2021
SMC Submission Type
Abbreviated
SMC Status
Restricted